Edition:
United States

Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

15.61EUR
24 Jul 2017
Change (% chg)

€0.00 (+0.00%)
Prev Close
€15.61
Open
€15.61
Day's High
€15.61
Day's Low
€15.61
Volume
21
Avg. Vol
11,473
52-wk High
€17.50
52-wk Low
€8.35

ALVXM.PA

Chart for ALVXM.PA

About

Vexim SA is a France-based company engaged in the medical sector. The Company develops invasive medical instruments used in preventing and treating vertebral fractures. The Company markets its flagship product, SpineJack, in Germany, the United Kingdom, Austria and Ireland under a agreement with Stryker Corp, in France via its... (more)

Overall

Beta: 0.32
Market Cap(Mil.): €118.92
Shares Outstanding(Mil.): 7.62
Dividend: --
Yield (%): --

Financials

  ALVXM.PA Industry Sector
P/E (TTM): -- 32.10 15.85
EPS (TTM): -0.36 -- --
ROI: -18.99 13.54 -8.31
ROE: -19.97 15.90 -7.95

BRIEF-Vexim Q2 sales rise to 5.7 million euros

* ANTICIPATES A CONTINUED STRONG GROWTH IN SALES IN SECOND PART OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 11 2017

BRIEF-Vexim says Anvisa approves Spinejack implants in Brazil

* HAS RECEIVED REGULATORY APPROVAL FROM ANVISA(1), BRAZIL'S NATIONAL HEALTH SURVEILLANCE AGENCY, IN ORDER TO COMMERCIALIZE SPINEJACK® IN BRAZIL.

May 29 2017

BRIEF-Vexim aims at reaching profitability on full year basis in 2017

* AIMS AT REACHING PROFITABILITY ON FULL YEAR BASIS IN 2017 AND FUTURE CASH FLOWS SHOULD ALLOW VEXIM TO SELF-FINANCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 17 2017

BRIEF-Vexim: in Q1, 19 pct growth of sales at 4.7 million euros

* Continued growth and adoption of SpineJack in Q1 2017: +19 pct growth of sales at 4.7 million euros ($5.0 million)

Apr 19 2017

BRIEF-Vexim launches Masterflow plus in Germany

* New product launch in Germany: Masterflow plus, a new product targeted at low energy osteoporotic fractures Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Apr 18 2017

BRIEF-Vexim FY operating loss narrows at 3.2 million euros

* FY operating loss 3.2 million euros ($3.46 million) versus loss of 4.8 million euros year ago

Mar 22 2017

BRIEF-Vexim announces another major step towards SpineJack commercialization in US

* Finalizes recruitment of patients for international clinical study, supporting the 510 (k) regulatory approval application to the FDA

Feb 21 2017

BRIEF-Vexim to initiate registration process of its products in China

* Strengthens its intellectual property protection for the Spinejack in Asia

Feb 02 2017

Earnings vs. Estimates